Francis Sebastian, King Tom, Zeidler Martin P
Department of Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Department of Dermatology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Front Med (Lausanne). 2024 Apr 18;11:1285772. doi: 10.3389/fmed.2024.1285772. eCollection 2024.
JAK/STAT pathway signalling is associated with both chronic inflammatory conditions such as psoriasis and haematological malignancies such as the myeloproliferative neoplasms (MPNs). Here we describe a 73yo female patient with a history of chronic plaque psoriasis, post-essential thrombocythemia myelofibrosis (MF) and a quality of life substantially impacted by both conditions. We report that 15 mg oral Methotrexate (MTX) weekly as a monotherapy is well tolerated, provides a substantial clinical improvement for both conditions and significantly improves quality of life. We suggest that the recently identified mechanism of action of MTX as a JAK inhibitor is likely to explain this efficacy and suggest that repurposing MTX for MPNs may represent a clinical- and cost-effective therapeutic option.
JAK/STAT信号通路与诸如银屑病等慢性炎症性疾病以及诸如骨髓增殖性肿瘤（MPN）等血液系统恶性肿瘤均相关。在此，我们描述了一位73岁的女性患者，她有慢性斑块状银屑病病史、原发性血小板增多症后骨髓纤维化（MF）病史，且这两种病症均对其生活质量产生了重大影响。我们报告称，每周口服15毫克甲氨蝶呤（MTX）作为单一疗法耐受性良好，对这两种病症均有显著的临床改善，并能显著提高生活质量。我们认为，最近确定的MTX作为JAK抑制剂的作用机制可能解释了这种疗效，并表明将MTX重新用于MPN的治疗可能是一种具有临床和成本效益的治疗选择。
